BMYCelgeneRunning, no new patients
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Lymphoma, Follicular
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 95 (final count)
- Started
- Aug 30, 2024
- Main results expected
- Jun 19, 2026
- Fully finished
- Nov 27, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants who achieve complete metabolic response (CMR) as assessed by Lugano criteria 2014
Measured over: Up to approximately 12 months from participant randomization
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06425302 · record last updated 2026-07-31 · checked 2026-11-09 15:47 UTC